Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Take Action Now!

Advocacy > Issues > FORCE Leads the Charge for Medicaid Coverage of Genetic Testing


Newsflash

6/26/2020
Provided feedback on the “Preparing for the Next Pandemic” white paper asking that it address high out-of-pocket costs for oral anticancer drugs in future pandemic relief efforts.

5/11/2020
Joined the Partnership to Improve Patient Care in a letter to the new VP for Patient Engagement at the Institute for Clinical and Economic Review (ICER), offering to partner in advancing patient engagement and patient-centeredness at ICER.

5/8/2020
Expressed support for increased diversity in clinical trials, signing onto an effort urging congressional leadership to include text from HR 913, the CLINICAL TREATMENT Act, in the next COVID-19 relief bill.  

5/4/2020
Collaborated with the All Cancers Congress in asking U.S. governors to require that all health insurers allow for up to 90-day medication supplies during the COVID crisis.

FORCE Leads the Charge for Medicaid Coverage of Genetic Testing

Insurance Coverage & Barriers

Overview

Genetic testing for increased susceptibility to breast, ovarian, and other cancers has become the standard of care for prevention and risk management in the U.S. Medicaid coverage of health services, however, is managed independently by each state. Of the 50 state Medicaid programs, only 4—Alabama, New Hampshire, North Carolina, and South Carolina—do not cover genetic counseling and/or testing for inherited genetic mutations such as BRCA1 or BRCA2. FORCE learned that the North Carolina Division of Medical Assistance (DMA) is reviewing its policy on offering genetic testing. We mobilized quickly to write comments and secured the support of over 30 partner nonprofit and medical professional organizations in an effort to encourage NC Medicaid to offer this invaluable service to its enrollees. Read the comments submitted on March 23, 2018.

The vast majority of health insurers see the value of identifying individuals who may carry an inherited genetic mutation that causes increased risk of cancer (if that person meets certain personal and/or family health history criteria). In fact, under the Affordable Care Act (ACA), many insurance plans are required to cover BRCA testing for women who qualify and other specified preventive services with no copay or cost-sharing.

Medicaid and Medicare are not bound by the ACA mandate. Most Medicare regions cover BRCA testing only if a woman has already been diagnosed with cancer. Four regions, representing 19 states, have more expansive policies that include multigene panel testing if more than one mutation may be indicated, as well as testing for men.

FORCE continues to advocate that all Americans—regardless of gender, cancer status, economic situation, or health insurance provider—should have access to evidence-based preventive services including, but not limited to:

We are hopeful that NC Medicaid will institute a policy that includes coverage of genetic counseling and testing for those who should receive it. Moving ahead, we plan to work with the other three state Medicaid programs that currently fail to provide access to cancer genetic services. 

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered